AZD Single Ascending Dose Study In Healthy Japanese Subjects
AZD Single Ascending Dose Study In Healthy Japanese Subjects
This is a single centre, open label, non-randomised study to access the safety, tolerability,
 pharmacokinetics and pharmacodynamics of AZD3043 following a single dose administration to
 Japanese subjects.
Inclusion Criteria:

 -  Healthy Japanese male and females of non-childbearing potential aged ≥20 to ≤ 45 with
 suitable veins for cannulation or repeated venepuncture.

 -  Body weight 45-90 kg and Body mass index (BMI) ≥18.0 and ≤27.0 kg/m2

 -  Clinically normal physical findings including supine blood pressure, pulse rate, ECG,
 and laboratory assessments in relation to age, as judged by the Investigator.

 Exclusion Criteria:

 -  History of any clinically significant disease or disorder which, in the opinion of the
 Investigator, may either put the subject at risk because of participation in the
 study, or influence the results or the subject's ability to participate in the study.

 -  History or presence of gastrointestinal, hepatic or renal disease or any other
 condition known to interfere with absorption, distribution, metabolism or excretion of
 drugs

 -  Any clinically significant illness/infection or medical/surgical procedure or trauma,
 as judged by the Principal Investigator, within 4 weeks of the first administration of
 investigational product.

 -  Any clinically significant abnormalities in clinical chemistry, haematology or
 urinalysis as judged by the Investigator